Golden Valley, Minnesota Clinical Trials

A listing of Golden Valley, Minnesota clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Partial-enteral Nutrition Protocol for Crohn's Disease

A novel dietary intervention combining a standardized IBD diet (IBD-AID) with supplementation from a pea protein plant-based oral nutrition supplement (ONS) (Kate Farms Peptide 1.5) to improve protein, calorie, and nutrient intake in adult patients experiencing a Crohn's disease flare starting new immunologic therapy. Additionally, this study will include objective …

University of Minnesota
 (6.2 away) Contact site
  • 0 views
  • 13 Aug, 2025
  • 1 location
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a …

Clinical Research Institute- Site Number : 8400080
 (4.5 away) Contact site
  • 0 views
  • 29 Nov, 2025
  • +30 other locations
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

rituximab fludarabine
lymphocytic leukemia
chronic lymphocytic leukemia
lymphoma
immunochemotherapy
University of Minnesota Masonic Cancer Center
 (6.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy …

clinical stage ivb gastric cancer ajcc v8
lymphadenopathy
sprue
recurrent disease
cancer
North Memorial Medical Health Center
 (2.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +254 other locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

ros1
systemic therapy
carboplatin
vitamin b12 level
stage iv non-small cell lung cancer
Minnesota Oncology Hematology, P.A.
 (5.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +27 other locations
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Vaccination

Hypothesis: Infections other than HIV can cause LN inflammation and collagen damage to the fibroblastic reticular cell network (FRCn), which will lead to CD4 T cell depletion and impaired vaccine responses. This protocol will study yellow fever vaccine (YFV) in two cohorts of people, one from Uganda and the other …

vaccination
yellow fever
immunosuppressive
University of Minnesota
 (6.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

crizotinib
schwartz
cataract
glioma
nf2 gene
Mayo Clinic (Site 908)
 (4.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

deficiency
imiglucerase
eliglustat
gaucher disease
Investigational Site Number 840046
 (5.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840114
 (5.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

replacement therapy
myozyme
gaa gene
deficiency
glycogen storage disease type ii
Investigational Site Number 840046
 (5.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations